On Monday, Novavax announced that its two-dose vaccination is highly effective against COVID-19.

This comes after its phase-three trial, in which 29,960 people participated, found that the vaccine has a 90.4% effectiveness against moderate and severe illness. The participants were located across 119 sites in the U.S. and Mexico.

Even more notably, among those in the high-risk populations, the drug was shown to have a 91 percent effectiveness rate. This population includes those over the age of 65 or those who suffer from comorbidities.


A week of political news in your in-box.
We find the news you need to know, so you don't have to.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Stanley C. Erck, the president and CEO of Novavax, said in a press release. “These clinical results reinforce that NVX-COV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.”

In that press release, Novavax also notes that once they complete final testing, they will file for regulatory authorizations. Once they are approved, the company said that they are on track to manufacture 100 million doses per month by the end of the third quarter alone.

After going through sequencing data, Novavax has also found that its vaccine is effective against 93.2 percent of variants.

The previously approved Pfizer-BioNTech and Moderna vaccine continue to present high effectiveness rates, which are 95 and 94.1, respectively.

Read more about:

Get the free uPolitics mobile app for the latest political news and videos

iPhone Android

Leave a comment